biostudies-literatureUnknown33(1)Ocal OBayerSirtex Medical<h4>Objectives</h4>To identify clinical and imaging parameters associated with progression of non-hypervascular hepatobiliary phase hypointense lesions during follow-up in patients who received treatment for hepatocellular carcinoma.<h4>Methods</h4>A total of 67 patients with 106 lesions were identified after screening 538 patients who underwent gadoxetic acid-enhanced MRI within the SORAMIC trial. All patients were allocated to the trial treatment according to the trial scheme, and 61 of 67 patients received systemic treatment with sorafenib (either alone or combined with locoregional therapies) during the trial period. Follow-up images after treatment according to trial scheme were reviewed for subsequent hypervascularization or > 1 cm size increase. The correlation between progression aEuropean radiology493-500https://www.ebi.ac.uk/biostudies/studies/S-EPMC9755078biostudies-literatureNon-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression.PMC9755078Fabritius MPOcal ORicke JPech MBerg Tvan Delden OBenito AVandecaveye VIezzi RSangro BSengel CBargellini ISeidensticker MGasbarrini ALoewe CZech CJMalfertheiner PGebauer BfalseNon-hypervascular hepatobiliary phase hypointense lesions detected in patients with hepatocellular carcinoma: a post hoc analysis of SORAMIC trial to identify risk factors for progression.<h4>Objectives</h4>To identify clinical and imaging parameters associated with progression of non-hypervascular hepatobiliary phase hypointense lesions during follow-up in patients who received treatment for hepatocellular carcinoma.<h4>Methods</h4>A total of 67 patients with 106 lesions were identified after screening 538 patients who underwent gadoxetic acid-enhanced MRI within the SORAMIC trial. All patients were allocated to the trial treatment according to the trial scheme, and 61 of 67 patients received systemic treatment with sorafenib (either alone or combined with locoregional therapies) during the trial period. Follow-up images after treatment according to trial scheme were reviewed for subsequent hypervascularization or > 1 cm size increase. The correlation between progression a2023-01-01T00:00:00Z2023 Jan2026-05-13T16:04:50.351Z2025-04-19T13:24:15.839ZS-EPMC97550783588118010.1007/s00330-022-09000-1